WATERTOWN, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc., a clinical-stage oncology therapeutics company with proprietary, proteomics-based technologies driving a new era of precision-based medicine, today announced the establishment of its scientific advisory board.
We are delighted to have these distinguished thought leaders in oncology research and development join our scientific advisory board, said Peter Blume-Jensen, M.D., Ph.D., chief executive officer and founder of Acrivon. Combined, they represent expertise across Acrivons key pillars of excellence including phospho-proteomics, predictive protein biomarkers, and oncology precision medicine. The caliber of this group, in addition to the high-quality investors who participated in our recent oversubscribed $100 million Series B financing, is a testament to the promise of our unique precision medicine platform.
George Demetri, M.D., professor at Harvard Medical School, co-director of the Ludwig Center, and senior vice president at the Dana-Farber Cancer Institute, added, I am very enthusiastic to help advance the potential benefit to patients from Acrivons pioneering proteomics-based precision medicine platform. The future of precision medicine lies in the ability to identify the right patients with complex cancers who can derive the maximal benefit from specific targeted therapies and rational combinations. Acrivons platform enables a unique approach to patient selection with the promise to be broadly applicable beyond the limitations of current tumor genome tests. We hope this will allow identification of direct mechanistic matching between the drug action with the primary drivers of malignancyin an individual patients tumor to predict treatment benefit with far less empiricism than current standards of care.
Scientific Advisory Board Members George Demetri, M.D., F.A.C.P., F.A.S.C.O., F.A.A.C.R. Dr. Demetri is co-director of the Ludwig Center at Harvard and professor of Medicine at Harvard Medical School and serves as senior vice president for experimental therapeutics at the Dana-Farber Cancer Institute (DFCI). Dr. Demetri was instrumental in the development of Gleevec (imatinib) as the first effective therapy for gastrointestinal stromal tumor (GIST) as a mutationally-driven solid tumor. His collaborative research efforts have contributed to worldwide regulatory approval of several other therapies, including sunitinib and regorafenib for GIST, as well as pazopanib, trabectedin, eribulin, and tazemetostat for other sarcomas. He is a member of the board of directors for Blueprint Medicines.
Dr. Demetri received his A.B. in Biochemistry at Harvard College and M.D. from Stanford Medical School. He completed his residency and chief residency at the University of Washington Hospitals in Seattle and his medical oncology fellowship at DFCI and Harvard Medical School. Dr. Demetri was the 2020 recipient of the David A. Karnofsky Memorial Award from the American Society of Clinical Oncology (ASCO).
Robert (Bob) Abraham, Ph.D. Dr. Abraham is executive vice president and head of cancer biology at Odyssey Therapeutics. Before that, he was most recently chief scientific officer at Vividion Therapeutics. Prior to Vividion, he was the senior vice president and world-wide head of the oncology R&D group at Pfizer. From 2005-2009, he was the head of oncology discovery research at Wyeth. During his tenure at Wyeth and Pfizer, Dr. Abraham contributed to the development of eight FDA-approved cancer drugs. Prior to joining industry, Dr. Abraham was a professor at the Sanford-Burnham-Prebys Medical Discovery Institute (SBPMDI) in La Jolla, CA, where he served as the director of the NCI-designated SBPMDI Cancer Research Center. Prior to SBPDMI, he was endowed chair in the Department of Pharmacology and Cancer Biology at the Duke University Medical Center. Prior to Duke University, Dr. Abraham held dual professorships in the departments of Immunology and Pharmacology at the Mayo Clinic in Rochester, MN. He maintains adjunct professor appointments at U.C. San Diego (Department of Pharmacology), and at the Sanford Burnham Prebys Institute.
Dr. Abraham began his career as an academic investigator, with enduring interests in cancer biology and immunology. His major research interests included characterization and functional analysis of the mammalian Target of Rapamycin (mTOR) signaling pathway, cancer metabolism, cellular signaling and DNA damage responses. Dr. Abraham has authored over 225 scientific publications, and his published work has been cited over 48,000 times. Dr. Abraham received his B.S. in Biology from Bucknell University and his Ph.D. in Pharmacology at the University of Pittsburgh, and he completed his postdoctoral training in Pharmacology and Immunology at the Mayo Clinic.
Timothy A. Yap, M.B.B.S., Ph.D., F.R.C.P. Dr. Yap is an associate professor in the departments for Investigational Cancer Therapeutics and Thoracic/Head and Neck Medical Oncology at the MD Anderson Cancer Center. He is also the medical director of the Institute for Applied Cancer Science, a drug discovery biopharmaceutical unit where drug discovery and clinical translation are seamlessly integrated. He is also an associate director of translational research at the Institute for Personalized Cancer Therapy, an integrated research and clinical trials program. Previously, Dr. Yap was a consultant medical oncologist at The Royal Marsden Hospital in London, UK and National Institute for Health Research BRC clinician scientist at The Institute of Cancer Research, London, UK.
Dr. Yaps primary research focuses on development of targeted agents and their acceleration through biomarker-driven clinical trials. His main interests include targeting of the DNA damage response as well as the development of novel immunotherapeutics, and past and currenthe is and/or has been a principal investigator for multiple clinical trials evaluating novel strategies for targeting the DNA damage response in cancer. Dr. Yap obtained his B.Sc. degree in Immunology and Infectious Diseases at Imperial College London, UK, and subsequently went on to attain his medical degree from Imperial College London, UK. He has a Ph.D. in Molecular Pharmacology from the Division of Cancer Therapeutics at the Institute of Cancer Research, London, UK.
David Berman, M.D., Ph.D. Dr. Berman is a professor and chair of the department of Pathology and Molecular Medicine at Queen's University in Kingston, Ontario. He is board certified in Anatomic Pathology and practices urologic surgical pathology at Kingston Health Sciences Centre while also running a biomarker discovery laboratory focused on urologic cancers. Dr. Berman earned his M.D. and Ph.D. (Genetics and Development) degrees from the University of Texas, Southwestern Medical Center. He completed residency training and a postdoctoral research fellowship at Johns Hopkins where he established his independent research laboratory, which moved to Canada in 2012. The Berman laboratory focuses on basic, translational, and clinical aspects of prostate and bladder cancer. His research has helped identify bladder cancer stem cells and druggable targets in embryonic signaling pathways, and it has helped improve surgical pathology practice.
Dr. Berman was director of the Queens Cancer Research Institute from 2015-2021 and has served on research advisory committees for the Canadian Cancer Society (ACOR), the Canadian Cancer Trials Group, and Bladder Cancer Canada. He currently leads a translational research effort for the Canadian Bladder Cancer Research Network.
Jesper Olsen, Ph.D. Dr. Olsen is an academic co-founder and head of phosphoproteomics at Acrivon Therapeutics, Inc. He is a professor in quantitative proteomics at the University of Copenhagen and vice director of the Novo Nordisk Foundation Center for Protein Research. Dr. Olsen is a pioneer in mass spectrometry based phosphoproteomics and its applications to decipher cell-signaling networks at a systems-wide scale, and his research interest is developing and applying phosphoproteomics technologies for comprehensive kinase drug profilings with clinical actionability. Dr. Olsen is the most cited phosphoproteomics expert world-wide and among top 0.1% in protein sciences.
Dr. Olsen received his M.Sc. in Analytical Chemistry at the University of Southern Denmark and his Ph.D. in Biochemistry and Molecular Biology at the same place under the supervision of Prof. Matthias Mann. Dr. Olsen completed his post-doctoral training in proteomics and cell signaling at the Max Planck Institute for Biochemistry in Munich. He is based in Copenhagen since 2009, where he joined the newly established Center for Protein Research, initially as group leader and since 2014 as vice director.
About Acrivon Acrivon is a clinical stage oncology company leveraging its unique, proprietary phosphoproteomics technology called Acrivon Precision Predictive Proteomics, or AP3, in development of its pipeline of oncology drugs. The AP3 platform enables the creation of drug-specific proprietary OncoSignature companion diagnostics that can be used to identify patients most likely to benefit from Acrivons medicines. Through its highly specific patient selection, the company seeks to accelerate clinical development and increase the probability of successful treatment outcome for patients. The companys pipeline includes the clinically advanced lead program, ACR-368 (also known as prexasertib), a targeted oncology asset in-licensed from Lilly which has demonstrated evidence of durable responses, in solid cancers in Phase 2 trials. Acrivon is also developing additional pipeline programs targeting critical nodes in DNA Damage Response (DDR) and cell cycle regulation. Please visit the companys website at https://acrivon.com for more information.
Acrivon Contacts: Alexandra Santos asantos@wheelhouselsa.com
Aljanae Reynolds areynolds@wheelhouselsa.com
See the original post:
Acrivon Therapeutics Announces its Scientific Advisory Board with Renowned Oncology Thought Leaders - The Bakersfield Californian
- Living with Lupus: Hematopoietic Stem Cell Therapy for Lupus [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Unlocking the Secrets of Blod Cell Therapy - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- Alzheimers Neurons Created from Pluripotent Stem Cells [Last Updated On: January 28th, 2012] [Originally Added On: January 28th, 2012]
- Verastem to Present at Molecular Medicine Tri-Conference Symposium “Targeting Cancer Stem Cells in Oncology” [Last Updated On: February 16th, 2012] [Originally Added On: February 16th, 2012]
- Plethora of New Products to be Showcased at 2012 Molecular Medicine Tri-Conference [Last Updated On: February 18th, 2012] [Originally Added On: February 18th, 2012]
- Leukaemia cells have a remembrance of things past [Last Updated On: April 26th, 2012] [Originally Added On: April 26th, 2012]
- Science Translational Medicine and the DMM Global Foundation Announce Days of Molecular Medicine 2012 "The ... [Last Updated On: July 13th, 2012] [Originally Added On: July 13th, 2012]
- Common RNA pathway found in ALS and dementia [Last Updated On: October 1st, 2012] [Originally Added On: October 1st, 2012]
- Culprits behind ALS and dementia share common pathway [Last Updated On: October 2nd, 2012] [Originally Added On: October 2nd, 2012]
- 22 Molecular Medicine—Cloning and Stem Cells - Video [Last Updated On: November 1st, 2012] [Originally Added On: November 1st, 2012]
- Stem Cells and the Future of Medicine - Larry Goldstein, Ph.D. at TEDxAmericasFinestCity - Video [Last Updated On: November 1st, 2012] [Originally Added On: November 1st, 2012]
- Program in Molecular Medicine - UMass Medical School ... [Last Updated On: September 26th, 2016] [Originally Added On: September 26th, 2016]
- Molecular medicine - Wikipedia, the free encyclopedia [Last Updated On: September 26th, 2016] [Originally Added On: September 26th, 2016]
- Department of Molecular Medicine - College of Veterinary ... [Last Updated On: September 26th, 2016] [Originally Added On: September 26th, 2016]
- Molecular Medicine - Graduate School of Biomedical ... [Last Updated On: September 26th, 2016] [Originally Added On: September 26th, 2016]
- Home - Weatherall Institute of Molecular Medicine [Last Updated On: October 20th, 2016] [Originally Added On: October 20th, 2016]
- Molecular Medicine - Wake Forest Baptist Health [Last Updated On: October 20th, 2016] [Originally Added On: October 20th, 2016]
- Cellular and Molecular Medicine Graduate Program [Last Updated On: October 20th, 2016] [Originally Added On: October 20th, 2016]
- International Masters Program Molecular Medicine ... [Last Updated On: October 20th, 2016] [Originally Added On: October 20th, 2016]
- LSUHSC School of Medicine - Biochemistry and Molecular Biology [Last Updated On: November 20th, 2016] [Originally Added On: November 20th, 2016]
- Molecular Medicine | Molecular Medicine Reports ... [Last Updated On: November 20th, 2016] [Originally Added On: November 20th, 2016]
- Precision medicine opens the door to scientific wellness preventive approaches to suicide - Medical Xpress [Last Updated On: August 15th, 2017] [Originally Added On: August 15th, 2017]
- New Hampshire biologist reacts to gene-editing discovery - The Union Leader [Last Updated On: August 15th, 2017] [Originally Added On: August 15th, 2017]
- The Human Heart May Have a Natural 'Backup Battery' - Healthline [Last Updated On: August 15th, 2017] [Originally Added On: August 15th, 2017]
- Georgia colleges gear up for new semester - AJC.com - Atlanta Journal Constitution [Last Updated On: August 15th, 2017] [Originally Added On: August 15th, 2017]
- Change in protein production essential to muscle function - Baylor College of Medicine News (press release) [Last Updated On: August 15th, 2017] [Originally Added On: August 15th, 2017]
- Clinical trial uses a genetically engineered virus to fight cancer - Medical Xpress [Last Updated On: August 15th, 2017] [Originally Added On: August 15th, 2017]
- A New Gene Editing Technique Could Finally Allow Us to Treat ALS - Futurism [Last Updated On: August 15th, 2017] [Originally Added On: August 15th, 2017]
- New Version of CRISPR Corrects RNA Defects Linked to ... - Technology Networks [Last Updated On: August 16th, 2017] [Originally Added On: August 16th, 2017]
- Circular RNA Linked to Brain Function - Technology Networks [Last Updated On: August 16th, 2017] [Originally Added On: August 16th, 2017]
- Yenepoya University to offer biotech skill enhancement programme - Hindu Business Line [Last Updated On: August 16th, 2017] [Originally Added On: August 16th, 2017]
- Spotlight Innovation Enters into Sponsored Research Agreement with Indiana University to Develop New Therapies for ... - PR Newswire (press release) [Last Updated On: August 16th, 2017] [Originally Added On: August 16th, 2017]
- Using barcodes to trace cell development - Medical Xpress [Last Updated On: August 16th, 2017] [Originally Added On: August 16th, 2017]
- What can genetic testing really tell you? - Popular Science [Last Updated On: August 17th, 2017] [Originally Added On: August 17th, 2017]
- Cancer Treatment Centers of America and Foundation Medicine Join Forces to Advance Precision Cancer Treatment - Markets Insider [Last Updated On: August 17th, 2017] [Originally Added On: August 17th, 2017]
- A New Method of 3D Printing Living Tissues - Technology Networks [Last Updated On: August 17th, 2017] [Originally Added On: August 17th, 2017]
- Spotlight Innovation Enters into Sponsored Research Agreement with Indiana University to Develop New Therapies for ... - Markets Insider [Last Updated On: August 17th, 2017] [Originally Added On: August 17th, 2017]
- MS in Molecular Medicine - Drexel University College of ... [Last Updated On: August 17th, 2017] [Originally Added On: August 17th, 2017]
- Master of Science (MSc) in Molecular Medicine - NTNU [Last Updated On: August 17th, 2017] [Originally Added On: August 17th, 2017]
- Molecular Medicine Research - Wake Forest School of Medicine [Last Updated On: August 17th, 2017] [Originally Added On: August 17th, 2017]
- New method for the 3D printing of living tissues - Scientist Live [Last Updated On: August 22nd, 2017] [Originally Added On: August 22nd, 2017]
- Bio-inspired Materials Give Boost to Regenerative Medicine - Bioscience Technology [Last Updated On: August 22nd, 2017] [Originally Added On: August 22nd, 2017]
- MSU Expanding Medical Research In Grand Rapids | WKAR - WKAR [Last Updated On: August 30th, 2017] [Originally Added On: August 30th, 2017]
- Stabilizing TREM2 a potential strategy to combat Alzheimer's disease - Medical Xpress [Last Updated On: August 30th, 2017] [Originally Added On: August 30th, 2017]
- TCI woman fell 31 floors, due to work in molecular medicine in Malaysia - Magnetic Media (press release) [Last Updated On: August 30th, 2017] [Originally Added On: August 30th, 2017]
- Molecular Medicine | University of Maryland School of Medicine [Last Updated On: August 30th, 2017] [Originally Added On: August 30th, 2017]
- Reconstructing life at its beginning, cell by cell - Phys.Org [Last Updated On: August 31st, 2017] [Originally Added On: August 31st, 2017]
- Dr. Pawel Muranski to Head New Cellular Immunotherapy Laboratory at NewYork-Presbyterian/Columbia University ... - Newswise (press release) [Last Updated On: August 31st, 2017] [Originally Added On: August 31st, 2017]
- Hofstra and Northwell rename medical school following $61 million donation - The Island Now [Last Updated On: August 31st, 2017] [Originally Added On: August 31st, 2017]
- TREM2 Cleavage Site Pinpointed: A Gateway to New Therapies? - Alzforum [Last Updated On: August 31st, 2017] [Originally Added On: August 31st, 2017]
- The Secret Ingredient That Stops Honeybees From Becoming Queens - New York Times [Last Updated On: August 31st, 2017] [Originally Added On: August 31st, 2017]
- What happened to precision medicine? - Phoenix Business Journal [Last Updated On: September 4th, 2017] [Originally Added On: September 4th, 2017]
- Fetal genes can increase the risk of illness during pregnancy - Medical Xpress [Last Updated On: September 4th, 2017] [Originally Added On: September 4th, 2017]
- Society of Nuclear Medicine and Molecular Imaging (SNMMI) [Last Updated On: October 1st, 2017] [Originally Added On: October 1st, 2017]
- For Authors - Molecular Medicine [Last Updated On: October 1st, 2017] [Originally Added On: October 1st, 2017]
- Center for Applied Proteomics and Molecular Medicine [Last Updated On: October 15th, 2017] [Originally Added On: October 15th, 2017]
- Nuclear Medicine - Molecular Imaging - Nuclear Medicine ... [Last Updated On: August 3rd, 2018] [Originally Added On: August 3rd, 2018]
- Proteomics Conferences 2018 | Molecular Medicine Congress ... [Last Updated On: August 21st, 2018] [Originally Added On: August 21st, 2018]
- Section of Molecular Medicine | Wake Forest School of Medicine [Last Updated On: November 9th, 2018] [Originally Added On: November 9th, 2018]
- Faculty Research - Department of Molecular Medicine ... [Last Updated On: February 14th, 2019] [Originally Added On: February 14th, 2019]
- Goethe-Universitt Molecular Medicine (Master of Science) [Last Updated On: March 5th, 2019] [Originally Added On: March 5th, 2019]
- Biochemistry and Molecular Biology at Miller School of ... [Last Updated On: March 30th, 2019] [Originally Added On: March 30th, 2019]
- Molecular Medicine Research - Mayo Clinic Research [Last Updated On: April 27th, 2019] [Originally Added On: April 27th, 2019]
- Molecular Medicine (MolMed) | Duke School of Medicine [Last Updated On: April 27th, 2019] [Originally Added On: April 27th, 2019]
- Molecular Medicine | Molecular, Cellular and Developmental ... [Last Updated On: April 27th, 2019] [Originally Added On: April 27th, 2019]
- Home | EMBO Molecular Medicine [Last Updated On: May 5th, 2019] [Originally Added On: May 5th, 2019]
- Molecular Medicine (formerly Molecular & Cellular Biology) [Last Updated On: June 3rd, 2019] [Originally Added On: June 3rd, 2019]
- The world's first psilocybin research center is opening in Jamaica - Big Think [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- Synthetic networks with tunable responsiveness, biodegradation, and molecular recognition for precision medicine applications - Science Advances [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- No place for racism: an open letter from University of Auckland staff - The Spinoff [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- XIST-Promoter Demethylation as Tissue Biomarker for Testicular Germ Cell Tumors and Spermatogenesis Quality - Beyond the Abstract - UroToday [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- Tulane researcher is editor of journal issue honoring 40th anniversary of key cancer discovery - News from Tulane [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- New insights into heart's healing capacity - Baylor College of Medicine News [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- Giving a Speed Boost to Nerve Regrowth - Technology Networks [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- Exploring the stress-mood-appetite connection - Baylor College of Medicine News [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- What's in the cards for this year's Nobel Prizes? - STAT [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- Treatment for Incurable Breast Cancer, Melanoma Improved by Adding Local Anesthetics - Newswise [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- DNA Nanomachines Are Opening Medicine to the World of Physics - Singularity Hub [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- Institute of Human Virology Hosts 21st Annual International Meeting of Top Scientists on Ending the HIV/AIDS Epidemic in America and the Intersection... [Last Updated On: October 5th, 2019] [Originally Added On: October 5th, 2019]
- Digital Biopsies: Radiomics and Pathomics Are Important Stops on the Path to Precision Medicine - Cancer Therapy Advisor [Last Updated On: October 5th, 2019] [Originally Added On: October 5th, 2019]